FTRE

#2114
Fortrea Holdings Inc. Common Stock
10.72
+2.29%
Sector:
Base:
Profit Currency:
Daily Range
10.72
10.72
Year Range
3.97
18.67
Daily Change
+2.29%
Monthly Change
-38.28%
6 month change
+18.45%
Year Change
-23.21%
Previous Close
10.48
Open
10.72
Bid
Ask
Low
10.72
High
10.72
Volume
122
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 959.44 M
  • Employee 15 K
  • Founded 2023
  • CEO Paul R. N. Kirchgraber
  • Website www.fortrea.com
  • Headquarter North Carolina, United States
  • FIGI BBG01GZF9VY6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.75
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Fortrea Holdings Inc

Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries. Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies. The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.

News